Feragen Raises Seed Capital for Pet Genetics Innovation

Salzburg-based Feragen, a specialist in animal genetic diagnostics, has successfully secured a six-figure equity investment from Raiffeisen Salzburg Start-Up eGen. This capital infusion is earmarked to accelerate the development of its innovative digital platform and fuel international market expansion. The company leverages advanced genetic analysis to enhance animal breeding programs, with a significant focus on canine genetics.

Founded in 2017 as a spin-off from university research initiated in 2012 by molecular biologist Anja Geretschläger, Feragen has evolved into a globally recognized diagnostics laboratory. The company now serves clients across numerous European nations. Anja Geretschläger leads research and development, while co-CEO Michael Geretschläger oversees sales and marketing, guiding the firm's strategic growth.

The investment from Raiffeisen Salzburg Start-Up eGen, represented by Bernhard Wimmer and Bernhard Tomasi, underscores the investor's confidence in Feragen's scientific foundation and commercial strategy. They highlighted Feragen's "scientific depth, clear growth strategy, and consistent integration of diagnostics and digitalization" as key factors. The firm operates within a growing market with significant societal impact, aligning perfectly with the investor's strategic objectives.

Feragen's proprietary digital platform empowers breeders, associations, and veterinarians to manage genetic data and analysis results efficiently. Currently, approximately 10,500 users utilize the platform, which tracks data for over 38,000 dogs. A standout feature, the 'DogMatching' tool, allows for pre-mating genetic compatibility assessments, aiming to mitigate hereditary disease risks and bolster the long-term genetic health of canine populations.

The diagnostic capabilities offered by Feragen can identify hundreds of inherited diseases, preventing their transmission to future generations. This is crucial for breeding organizations and individual breeders seeking to preserve genetic diversity, reduce animal suffering, and cultivate healthier populations. The newly acquired funding will be instrumental in enhancing these digital offerings and penetrating new international territories, positioning Feragen for significant growth in the global pet diagnostics sector.

Anja Geretschläger expressed her satisfaction with the partnership, stating, "Finding an investor who understands that our analyses are rooted in research, not just a quick product, is rare. With Raiffeisen, we've found that partner right in our backyard. Their trust is both encouragement and a commitment." Michael Geretschläger added, "Raiffeisen Salzburg Start-Up eGen's regional focus and long-term investment philosophy resonate with our own values. This support enables us to accelerate our international expansion and scale our platform."

The global pet care market is experiencing robust expansion, driven by increasing pet ownership and a growing willingness among owners to invest in their pets' health and well-being. Within this, the pet diagnostics segment is seeing heightened interest due to advancements in genetic testing and a greater understanding of hereditary conditions. Feragen's focus on providing actionable genetic insights places it at the forefront of this evolving industry, with ambitions to become a world leader in pet genetics.